IDN 7314

Drug Profile

IDN 7314

Alternative Names: IDN-7314

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator Conatus Pharmaceuticals
  • Class Hepatoprotectants
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Primary sclerosing cholangitis

Most Recent Events

  • 26 Jun 2017 Preclinical trials in Primary sclerosing cholangitis in USA (PO)
  • 26 Jun 2017 IDN 7314 receives Orphan Drug status for Primary sclerosing cholangitis in USA
  • 26 Jun 2017 Updated pharmacodynamics data from a preclinical trial in primary sclerosing cholangitis released by Conatus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top